Abstract

PurposeTo identify CD8+ T cell-related factors and the co-expression network in melanoma and illustrate the interactions among CD8+ T cell-related genes in the melanoma tumor microenvironment.MethodWe obtained melanoma and paracancerous tissue mRNA matrices from TCGA-SKCM and GSE65904. The CIBERSORT algorithm was used to assess CD8+ T cell proportions, and the “estimate” package was used to assess melanoma tumor microenvironment purity. Weighted gene co-expression network analysis was used to identify the most related co-expression modules in TCGA-SKCM and GSE65904. Subsequently, a co-expression network was built based on the joint results in the two cohorts. Subsequently, we identified the core genes of the two most relevant modules of CD8+T lymphocytes according to the module correlation, and constructed the signature using ssGSEA. Later, we compared the signature with the existing classical pathways and gene sets, and confirmed the important prognostic significance of the signature in this paper.ResultsNine co-expressed genes were identified as CD8+ T cell-related genes enriched in the cellular response to interferon−gamma process and antigen processing and presentation of peptide antigen. In the low expression level group, inflammation and immune responses were weaker. Single-cell sequencing and immunohistochemistry indicated that these nine genes were highly expressed in CD8+ T cells group.ConclusionWe identified nine-gene signature, and the signature is considered as the biomarker for T lymphocyte response and clinical response to immune checkpoint inhibitors for melanoma

Highlights

  • Melanoma is one of the deadliest forms of skin cancer

  • We identified nine-gene signature, and the signature is considered as the biomarker for T lymphocyte response and clinical response to immune checkpoint inhibitors for melanoma

  • By comparing several classical scores previously proposed, we found that 9-gene signature has a good predictive ability for the prognosis and survival of melanoma patients, and can be used as one of the biomarkers to evaluate the response to immunotherapy

Read more

Summary

Introduction

Melanoma is one of the deadliest forms of skin cancer. In addition to external causes such as ultraviolet radiation, familial genetic factors cannot be ignored. Patients with melanoma diagnosed early and treated surgically had higher survival rates, and those with advanced metastatic melanoma had lower survival rates [1]. Melanoma treatment has included conventional chemotherapy and radiation therapy and therapies targeting B-raf proto-oncogene, serine/threonine kinase (BRAF), and MAP kinase-ERK kinase. The emergence of immune checkpoint inhibitors has extended survival from metastatic melanoma. Ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, and the programmed cell death protein (PD-1) antibodies nivolumab and pembrolizumab are widely used for immunotherapy [2]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call